Compare Crispr Therapeutics AG (CRSP) vs National Beverage Corp. (FIZZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs National Beverage Corp. — how do they compare? Crispr Therapeutics AG trades at $53.39 (market cap $4.88B), while National Beverage Corp. trades at $30.52 (market cap $2.89B). The key difference: Crispr Therapeutics AG is the larger of the two by market cap, and Crispr Therapeutics AG is trading nearer its 52-week high, National Beverage Corp. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and National Beverage Corp. for 33 Days on average.
| CRSP | FIZZ | |
|---|---|---|
Market Cap | $4.88B | $2.89B |
Volume | 2,861,747 | 553,950 |
Sector | Health | Consumer Staples |
52-Week High | $74.92 | $37.73 |
52-Week Low | $44.34 | $29.20 |
Typical Hold Time | 77 Days | 33 Days |
Enterprise Value | $3.30B | $2.84B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $50.44, down 3.65% amid bearish technical signals. The company shows negative profitability with -$581.60M net income and -4,101.26% net margin for 2025, though Q2 2026 EPS beat expectations. Positive analyst sentiment persists with 57.9% buy ratings and $67.83 consensus target. Recent clinical data presentations and CASGEVY commercial progress provide catalysts.
The stock faces fundamental challenges with persistent losses and negative cash flow from operations, but maintains Wall Street support for its gene-editing pipeline. Key risks include clinical trial outcomes and cash burn, while potential upside hinges on successful drug commercialization and upcoming data readouts through 2026.
National Beverage Corp. (FIZZ) trades at $30.84, up 4.19% today, showing bullish technical signals despite recent earnings misses. The company maintains solid fundamentals with $1.2B revenue, 14.81% net margin, and strong ROE of 40.13%, though growth has stalled with flat revenue trends. Recent news highlights margin pressure from input costs and a special $3.25 dividend payment in July 2026.
Outlook remains cautious with 50% analyst sell ratings reflecting growth concerns, while technical strength near support at $30 offers short-term stability. Key risks include persistent margin compression and competitive pressures in the beverage sector, though valuation at 16.58 P/E appears reasonable for current earnings power.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About National Beverage Corp.
National Beverage Corp is one of the top 10 non-alcoholic beverage companies in the U.S. Its portfolio skews toward functional drinks (that is those purporting to offer health benefits) and is anchored by the popular LaCroix sparkling water trademark. Other offerings include Rip It energy drinks, Everfresh juices, and soda brands like Shasta and Faygo. The firm controls most of its production and distribution apparatus, with very little outsourcing. In terms of go-to-market, it uses warehouse distribution for big-box retailers, direct-store-delivery for convenience stores and other small outlets, and food-service distributors for the food-service channel (schools, hospitals, restaurants). It is controlled by chairman and CEO Nick Caporella, who owns over 73% of the common stock.
Read more on FIZZ →
